Trial · NCT06780215
Efficacy of Varenicline Tartrate in Treating Frequent Premature Ventricular Contractions
NCT06780215, Phase 2, Completed, Yihan Chen
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Varenicline Tartrate in Treating Frequent Premature Ventricular Contractions. Trials, record NCT06780215. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06780215
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Varenicline Tartrate in Treating Frequent Premature Ventricular Contractions
- NCT number
- NCT06780215
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 116 participants, actual
- Lead sponsor
- Yihan Chen
- Conditions
- Premature Ventricular Contraction (PVC)
- Interventions
- Varenicline Tartrate Tablets, Placebo
- First posted
- 2025-01-17
- Last updated
- 2025-11-19
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage reduction in the average 24-hour count of premature ventricular contractions | Week 6 | |
| Secondary | The responder rate for premature ventricular contractions (PVCs) . | At Weeks 4, 6, and 8. | PVC responder: A participant is considered a responder if there is a ≥ 50% reduction from baseline in the 24-hour mean PVC count following treatment with either varenicline or placebo. |
| Secondary | The incidence of non-sustained ventricular tachycardia (NSVT). | At Weeks 4, 6, and 8. | If the 72-hour ECG monitoring shows a non-zero value for the number of NSVT episodes, it will be considered as "occurrence." If the number is zero, it will be considered as "non-occurrence." The incidence of NSVT at Weeks 4, 6, and 8 will be calculated by dividing the number of participants with NSVT episodes recorded by the 72-hour AECG monitoring by the total number of participants in each group, and then multiplying by 100%. |
| Secondary | Changes from baseline in the average 24-hour count and burden of premature ventricular contractions | Weeks 4, 6, and 8 | |
| Secondary | Changes from baseline in the average 24-hour number of episodes and burden of non-sustained ventricular tachycardia | Weeks 4, 6, and 8 | |
| Secondary | Change from baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) score | Week 6 | The KCCQ score ranges from 0 to 100, with higher scores indicating better outcomes. |
| Other | Safety End Points: The cumulative incidence of the first occurrence of malignant ventricular arrhythmias (time-to-first event) , including sustained ventricular tachycardia (SVT), ventricular fibrillation (VF), or ventricular flutter (VFL). | From randomization through Weeks 4, 6, and 8. | The malignant ventricular arrhythmia events will be adjudicated by the Central Adjudication Committee (CEC) based on planned 72-hour continuous ambulatory electrocardiography (AECG) monitoring and unplanned clinical evidence, including emergency or inpatient 12-lead ECG, bedside monitoring or telemetry ECG, implantable cardioverter defibrillator (ICD) records, or cardiopulmonary resuscitation (CPR) records, using a standardized approach. An event will be counted if any of these criteria are met; each participant will be counted for a maximum of one event. The event time will be taken as the earliest verifiable evidence. The analysis will be based on the risk set starting from randomization. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41778949 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06780215
GET https://conductscience.org/api/trials/v1/NCT06780215/registered